Aug 5, 2026 04:05PM
Jun 25, 2026 06:17AM
Jun 22, 2026 08:01AM
Jun 22, 2026 08:00AM
May 21, 2026 05:00PM
May 19, 2026 08:00AM
May 19, 2026 08:00AM Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
May 5, 2026 04:05PM
Feb 10, 2026 04:05PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM
Feb 2, 2026 08:00AM
Mar 26, 2025 01:08PM
Mar 26, 2025 01:07PM Exelixis (EXEL) PT Raised to $33 at Leerink Partners
Feb 11, 2025 04:05PM
Jan 24, 2025 02:31PM
Jan 24, 2025 02:30PM
Jan 13, 2025 12:50PM
Jan 12, 2025 04:00PM
Jan 9, 2025 09:00AM
Nov 27, 2024 07:08AM Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
Nov 26, 2024 04:05PM
Oct 29, 2024 04:05PM
Oct 16, 2024 06:54AM
Oct 16, 2024 06:03AM
Sep 16, 2024 02:01PM
Sep 16, 2024 08:45AM
Sep 16, 2024 08:45AM Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Aug 6, 2024 04:05PM
Aug 6, 2024 08:30AM
Aug 6, 2024 08:30AM
Feb 14, 2024 08:30AM
Nov 2, 2021 04:05PM
Sep 20, 2021 11:30AM
Sep 20, 2021 11:30AM Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO
Sep 17, 2021 04:24PM
Sep 17, 2021 04:23PM
Aug 5, 2021 04:05PM
Aug 5, 2021 08:01AM
Aug 5, 2021 08:00AM
Apr 29, 2021 06:59AM
Jan 22, 2021 01:10PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Jan 10, 2021 04:00PM
Nov 5, 2020 04:05PM
Nov 5, 2020 06:59AM
Oct 19, 2020 07:00AM
Oct 19, 2020 06:59AM
Dec 5, 2018 01:33AM
Nov 15, 2018 01:32AM Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Nov 1, 2018 04:05PM

15,656 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All